Southeast Asian countries have adopted a four-tier risk classification system (Class A, B, C, D) aligned with the ASEAN Medical Device Directive (AMDD) for medical device risk management. Although the naming of risk classes varies slightly across countries, the underlying logic is highly consistent, categorizing devices based on their potential risks to human body from low to high.
| Risk Level | Singapore | Vietnam | Malaysia | Indonesia | Thailand |
|---|---|---|---|---|---|
Low Risk | Class A | Class A | Class A | Class I / Class A | Type/class 1 |
Low to Medium Risk | Class B | Class B | Class B | Class II / Class B | Type/class 2 |
Medium to High Risk | Class C | Class C | Class C | Class III / Class C | Type/class 3 |
High Risk | Class D | Class D | Class D | Class IV / Class D | Type/class 4 |
For registration of overseas medical device manufacturers, five Southeast Asian countries (Singapore, Vietnam, Malaysia, Indonesia and Thailand) all mandate the appointment of a local agent or representative (LAR/AR) as the legal responsible person. This is a unified regulatory threshold established by Southeast Asian countries to ensure the compliance, traceability and clear legal liability attribution of imported medical devices in the local market.
| Country | Local Agent Title | Core Mandatory Requirements |
|---|---|---|
Singapore | Registrant | A legal entity that applies for and obtains medical device registration approval in accordance with local regulations |
Vietnam | Authorized Representative (AR) | The registration holder must be a local enterprise |
Malaysia | Authorized Representative (AR) | Must be a locally registered company or citizen with relevant qualifications |
Indonesia | PAK (Medical Device Distributor) / PKRT Importer, Co-branding Partner | For imported products of the same trademark/model, only one designated PAK/PKRT importer is allowed to act as the exclusive local authorized representative to hold the certificate and conduct agency services |
Thailand | Local Importer / Local Authorized Representative | Must first obtain the Establishment Licensing issued by TFDA before submitting product registration applications |
Based on the diverse overseas development needs of Chinese medical device enterprises, we have summarized three solutions for your reference.
Option 1: Route for Global Brand Expansion
Core Strategy: Leverage regional mutual recognition benefits under Singapore HSA framework
Chinese medical device manufacturers targeting long-term international brand development across the ASEAN region are advised to prioritize registration approval from Singapore HSA.
The Singapore Health Sciences Authority (HSA) is widely acknowledged as Southeast Asia’s most efficient and authoritative regulatory body with globally recognized certification credibility. Products approved by HSA are eligible for newly implemented regional mutual recognition policies effective 2025–2026 and serve as a critical reference certification for worldwide market access. Key benefits include:
● Singapore is designated as an independent reference authority under Thailand’s Reliance Scheme; existing HSA approval significantly shortens Thailand’s market access timeline.
● Under the ongoing Singapore-Malaysia regulatory mutual recognition pilot scheme, review duration for Malaysia registration can be cut by around 30 working days.
Option 2: Expedited Registration Route
Core Strategy: Take full advantage of preferential ASEAN policies recognizing China NMPA certification.
Vietnam Fast-Track Review: China has been newly listed as a reference country by Vietnam. High-risk Class C/D devices with valid China NMPA marketing approval qualify for accelerated review to drastically shorten approval lead time; registration for low-risk Class A/B products also proceeds efficiently.
Option 3: Route with Localized Production Layout
For markets reliant heavily on imported goods with heavy import tariff barriers, manufacturers can realize offshore production via joint venture construction or corporate acquisition. Such local manufacturing satisfies local preferential procurement policies for domestically-manufactured TKDN-qualified devices and avoids excessive import duties.
For instance, Thailand offers expedited registration for enterprises with in-country production sites; Malaysia’s 10-Year Biotechnology Incentive Programme provides tax incentives for locally-based manufacturers to reduce both capital expenditure and lead time.
Companies shall finalize their ASEAN medical device registration strategy in line with their localized manufacturing development blueprint.
